sumatriptan has been researched along with Dysgeusia in 1 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Dysgeusia: A condition characterized by alterations of the sense of taste which may range from mild to severe, including gross distortions of taste quality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sumatriptan was then launched as an oral tablet, shortly followed by the development of second-generation triptans that are now available in several formulations." | 2.42 | Clinical applications of new therapeutic deliveries in migraine. ( Dahlöf, C, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahlöf, C | 1 |
1 review available for sumatriptan and Dysgeusia
| Article | Year |
|---|---|
Clinical applications of new therapeutic deliveries in migraine.
Topics: Administration, Intranasal; Administration, Oral; Adult; Clinical Trials as Topic; Dysgeusia; Female | 2003 |